CTIS2023-504038-23-00进行中（未招募）1 期
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung) - BO39610
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 314
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed metastatic, non-squamous or squamous NSCLC, Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status by means of central testing, Stage 1 and 2 Measurable disease according to Response Evaluation Criteria in Solid Tumors, Version 1.1, Stage 1 and 2 Negative HIV test at screening, Stage 1 and 2 Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus DNA test at screening, Stage 1 and 2 Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
排除标准
- •Activating mutation in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangement, Prior allogeneic stem cell or solid organ transplantation, Treatment with systemic immunostimulatory agents within 4 weeks (or 5 half-lives of the drug, whichever is longer) or systemic immunosuppressive medication within 2 weeks prior to study treatment start, History of malignancy other than NSCLC within 2 years prior to screening with the exception of malignancies with a negligible risk of metastasis or death, Active tuberculosis, Severe infection within 4 weeks prior to initiation of study treatment
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma Morpheus-UCrothelial carcinoma (UC)MedDRA version: 20.0Level: LLTClassification code: 10064467Term: Urothelial carcinoma Class: 10029104CTIS2024-511316-25-00F. Hoffmann-La Roche AG395
招募中
1 期
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC)Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2023-503629-20-00F. Hoffmann-La Roche AG185
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Multiple Treatment Combinations in Patients with Breast Cancer (Morpheus- Breast Cancer)Breast cancerCTIS2023-507495-48-00F. Hoffmann-La Roche AG210
进行中（未招募）
1 期
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus–Pancreatic Cancer)Pancreatic ductal adenocarcinoma (PDAC)MedDRA version: 21.0Level: LLTClassification code: 10033604Term: Pancreatic cancer Class: 10029104CTIS2024-511271-15-00F. Hoffmann-La Roche AG282
进行中（未招募）
1 期
Tepotinib with Gefitinib in Subjects with Locally Advanced or Metastatic NSCLC (INSIGHT)ocally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001604-28-NLMerck KGaA156